Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following cleft palate surgery in infants and young children.
This is a single center, randomized, double blind, parallel-group dose escalation investigation in infants and children undergoing cleft palate surgery which will compare post operative pain control indices for patients receiving short acting versus long acting opioids as perioperative analgesics. Surgical and anesthesia care, except for opioid management, are not altered for study purposes. Subjects are randomized 2:1 to either long-duration (methadone) or short-duration opioid (fentanyl, hydromorphone) through the perioperative period. Exploratory data will be collected for up to 30 days post-operatively.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Methadone | Active Comparator | Methadone 0.2-0.25 mg/kg actual body weight |
|
| Fentanyl/Hydromorphone | Active Comparator | Fentanyl/Hydromorphone per routine care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methadone hydrochloride | Drug | Initial dosing 0.2mg/kg, potential to escalate to 0.25mg/kg following interim analysis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total amount of opioids medication administered | Post-PACU in-hospital opioid use in oral morphine milligram equivalents (OMEs) per kilogram through POD1 | From PACU discharge through postoperative day 1 (POD1) |
| Measure | Description | Time Frame |
|---|---|---|
| Total amount of opioid medications administered | Total (post-PACU in-hospital and post-discharge) opioids used (number of daily doses and OME/kg) | Up to 7 days after surgery |
| Postanesthesia Care Unit (PACU) opioid medication administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lisa M. Einhorn, M.D. | Contact | 919 970 2805 | lisa.einhorn@duke.edu |
| Name | Affiliation | Role |
|---|---|---|
| Lisa M. Einhorn, M.D. | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Recruiting | Durham | North Carolina | 27705 | United States |
De-identified data will be shared at the discretion of the PI upon reasonable request.
IPD will be available 1 year after study completion.
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002972 | Cleft Palate |
| D010146 | Pain |
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D007569 | Jaw Abnormalities |
| D007571 | Jaw Diseases |
| D009140 | Musculoskeletal Diseases |
| D019767 | Maxillofacial Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D008691 | Methadone |
| D005283 | Fentanyl |
| D004091 | Hydromorphone |
| ID | Term |
|---|---|
| D007659 | Ketones |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fentanyl/Hydromorphone | Drug | Per routine care |
|
Binary (yes/no) need for opioid administration in the PACU
| Up to 6 hours after surgery |
| Area under the curve (AUC) pain trajectories | In-hospital AUC pain trajectories calculated from pain intensity scores on the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale. The FLACC pain scale has a range of 0 to 10, where 0=no pain and 10=worst possible pain. | Through hospital discharge (up to 4 days) |
| Average daily pain intensity | Average daily pain scores using the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale. The FLACC pain scale has a range of 0 to 10, where 0=no pain and 10=worst possible pain. | Up to 7 days after surgery |
| D019465 |
| Craniofacial Abnormalities |
| D009139 | Musculoskeletal Abnormalities |
| D009057 | Stomatognathic Diseases |
| D009056 | Mouth Abnormalities |
| D009059 | Mouth Diseases |
| D018640 | Stomatognathic System Abnormalities |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009422 | Nervous System Diseases |
| D006571 |
| Heterocyclic Compounds |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |